Iacoboni Gloria, Morschhauser Franck
Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Department of Hematology, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France.
Blood. 2025 Jan 9;145(2):170-175. doi: 10.1182/blood.2024025699.
Follicular lymphoma (FL) usually requires multiple lines of therapy, and disease control remains largely insufficient with conventional chemoimmunotherapy. Several T-cell-redirecting strategies recently approved in the relapsed/refractory setting have the potential to improve outcomes and change the treatment algorithm in FL. This review focuses on the role of chimeric antigen receptor T cells and bispecific antibodies in FL, paying special attention to sequencing approaches and future directions.
滤泡性淋巴瘤（FL）通常需要多线治疗，而传统的化疗免疫疗法在疾病控制方面仍存在很大不足。最近在复发/难治性情况下获批的几种重定向T细胞策略有可能改善治疗效果并改变FL的治疗方案。本综述重点关注嵌合抗原受体T细胞和双特异性抗体在FL中的作用，特别关注治疗顺序和未来方向。
